Integra LifeSciences Holdings (IART)

Gross profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Gross profit (ttm)	US$ in thousands	50,166	32,483	53,450	58,393	98,398	135,593	173,497	219,501	227,718	221,530	213,212	198,139	221,050	420,642	586,215	681,255	851,034	855,121	856,159	942,946
Revenue (ttm)	US$ in thousands	1,596,615	1,533,335	1,521,985	1,473,066	1,486,381	1,488,778	1,493,656	1,509,844	1,505,291	1,519,581	1,519,648	1,510,233	1,535,982	1,529,270	1,504,267	1,371,086	1,317,264	1,323,744	1,339,441	1,466,719
Gross profit margin		3.14%	2.12%	3.51%	3.96%	6.62%	9.11%	11.62%	14.54%	15.13%	14.58%	14.03%	13.12%	14.39%	27.51%	38.97%	49.69%	64.61%	64.60%	63.92%	64.29%

December 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $50,166K ÷ $1,596,615K
= 3.14%

Integra LifeSciences Holdings has experienced a gradual decline in its gross profit margin over the past few years, as evidenced by the provided data. The gross profit margin decreased from 64.29% in March 2020 to 3.14% in December 2024.

This significant decline indicates challenges in maintaining profitability while managing the cost of goods sold. Factors such as increasing production costs, pricing pressures, or changes in sales mix could have contributed to this trend.

It is crucial for the company to closely monitor and address the factors impacting its gross profit margin to sustain long-term profitability and competitiveness in the market. Measures to improve operational efficiency, cost control, and pricing strategies may be necessary to reverse the declining trend and enhance profitability moving forward.